Skip to main content
. Author manuscript; available in PMC: 2015 May 27.
Published in final edited form as: Clin Cancer Res. 2012 Jan 10;18(4):1004–1014. doi: 10.1158/1078-0432.CCR-11-0383

Figure 5.

Figure 5

Receiver operator characteristic curve analysis of the ability of the CD10+ stroma signature and the A-score to discriminate patients with pathologic complete response from patients with residual disease in the TOP trial: all ER patients (A), ER/HER2 (B), and ER/HER2+ (C). AUC, area under the curve.